Navigation Links
University of Vermont Health Network Ventures and Wilson Sonsini Goodrich & Rosati Invest in Biofactura, Inc.
Date:6/1/2019

The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round.

“With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as we advance our biopharmaceutical products to the clinic,” said Darryl Sampey, BioFactura’s President and CEO.

Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer, stated, “We are excited to work with the University of Vermont Health Network Ventures and WSGR and view them as important strategic investors in BioFactura. Both our Biosimilars and Biodefense drugs promote the health and safety of our patients using innovative, state of the art, biopharmaceutical manufacturing techniques. Improving access to highly effective biologic therapeutics, while bending the cost curve downwards in a meaningful way, are shared goals.”

Chris Jones, Director of Venture Investments for the UVM Health Network, commented, "Investments into biosimilars are directly aligned with the mission of improving access to care and reducing costs. There are additional benefits that BioFactura has revealed, such as improved quality and emergency preparedness, and I predict we will be seeing a lot of interest in this space and in this company going forward."

Charles Andres Ph.D., RAC, Associate Attorney specializing in Intellectual Property states, “WS Investments, the investment fund of Wilson, Sonsini, Goodrich & Rosati, was pleased to participate in the round.”

About BioFactura, Inc.
BioFactura, Inc. (Frederick MD) develops and commercializes high-value, highly similar biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases. http://www.biofactura.com

About University of Vermont Health Network Ventures
University of Vermont Health Network Ventures is the highly selective, mission-led ventures arm of Vermont’s 6-hospital healthcare system. http://www.uvmhealth.org

About Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a law firm in the United States that specializes in business, securities, and intellectual property law. WSGR provides legal services to technology, life sciences, and growth enterprises worldwide, as well as the venture capital firms, private equity firms, and investment banks that finance them. The firm's clients operate in a range of technology industries, including the biotech, communications, digital media, energy, financial services, medical devices, mobile, semiconductor, and software sectors. http://www.wsgr.com

Read the full story at https://www.prweb.com/releases/university_of_vermont_health_network_ventures_and_wilson_sonsini_goodrich_rosati_invest_in_biofactura_inc/prweb16288101.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Awards Grant to Stanford University to Study the Effect of Semen Microbiome on Fertilization and Embryo Development
2. Sensors Midwest Partners with Fraunhofer USA and Sonoma State University, CA, to host IoT Enabled Industry 4.0 Certification Workshop
3. Stephen Zarrilli Named President & CEO of University City Science Center
4. IBM Research and Cornell University to Use Genetic Sequencing and Big Data Analytics to Help Keep Global Milk Supply Safe
5. Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas
6. Temple University School of Medicine receives Grand Challenges Explorations grant
7. BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree
8. University of Delaware study connects penguin chick weights to local weather conditions
9. Johannes Gutenberg University Mainz joins Germanys Gauss-Allianz as a full member
10. The Genome Institute at Washington University Receives Irys System from BioNano Genomics to Advance Research for Genome Reference Consortium
11. University of Washington biotech start-up to develop game-changing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... ... Suvoda LLC , a SaaS provider of Interactive Response Technology (IRT) ... Inc. Magazine’s Best Workplaces for 2019, Inc.’s fourth annual ranking of the fast-growing private ... the newsstands on May 28, is the result of a comprehensive measurement of private ...
(Date:5/21/2019)... ... , ... Dr. David Greene , Founder and CEO of R3 Stem ... to the Rescue, was produced by Award Winning filmmaker Dr. Elliott Haimoff. , In ... the safety of the procedures along with the potential for helping patients avoid potentially ...
(Date:5/21/2019)... Pa. (PRWEB) , ... May 20, 2019 , ... ... for the health care field, today announced a 96.15% pass rate for first-time ... of 2019. This surpasses the national average of 76.43% by nearly 20 points. ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology ... the appointment of Biofeedback Tech Ltd as its authorised distributor for ... part of many therapeutic treatments and clinical assessment protocols to treat stress related ...
(Date:6/11/2019)... Calif. (PRWEB) , ... June 11, 2019 , ... ... company of Personalized Stem Cells Inc. (PSC) , has announced that their ... Public Health, Food and Drug Branch for manufacturing. This is an important ...
(Date:5/31/2019)... , ... May 29, 2019 ... ... patent applications from the USPTO providing proprietary interest to our methodology, processes, ... SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), ... million Series A funding round co-led by Astanor Ventures and Talis ... Fund and iSelect Fund . The company has raised $11.75m to date ...
Breaking Biology Technology: